PASG - Passage Bio, Inc. News

Passage Bio Q2 EPS $(2.44) Beats $(3.47) Estimate

Passage Bio (NASDAQ:PASG) reported quarterly losses of $(2.44) per share which beat the analyst cons

12 Health Care Stocks Moving In Thursday's Intraday Session

Gainers Atlantic International (NASDAQ:ATLN) shares increased by 41.0% to $1.1 during Thursday'

12 Health Care Stocks Moving In Thursday's Pre-Market Session

Gainers Adicet Bio (NASDAQ:ACET) stock moved upwards by 22.9% to $10.14 during Thursday's pre-m

seekingalpha.com

Passage Bio, Inc. (PASG) M&A Call Prepared Remarks Transcript

9 Health Care Stocks Moving In Wednesday's After-Market Session

Gainers American Shared Hospital (AMEX:AMS) stock rose 14.2% to $1.61 during Wednesday's after-

Passage Bio, Remix Therapeutics Sign All-Stock Business Combination Agreement; Combined Entity To Op

Passage Bio, Inc. (Nasdaq: PASG) ("Passage Bio") and Remix Therapeutics, Inc. ("Remix&#3

Passage Bio and Remix Therapeutics Announce Merger Agreement

Combined company to operate as Remix Therapeutics and advance Remix's pipeline of novel small molecu

Chardan Capital Downgrades Passage Bio to Neutral, Lowers Price Target to $7

Chardan Capital analyst Janani Sundararajan downgrades Passage Bio (NASDAQ:PASG) from Buy to Neut

This Mohawk Industries Analyst Is No Longer Bullish; Here Are Top 2 Downgrades For Tuesday

Wall Street analysts changed outlook for top names, including downgrading Mohawk Industries and Pass

Oppenheimer Maintains Outperform on Passage Bio, Lowers Price Target to $15

Oppenheimer analyst Jay Olson maintains Passage Bio (NASDAQ:PASG) with a Outperform and lowers th

Wedbush Downgrades Passage Bio to Neutral, Lowers Price Target to $8

Wedbush analyst Yun Zhong downgrades Passage Bio (NASDAQ:PASG) from Outperform to Neutral and low

Crude Oil Surges Over 6%; Investar Holding Shares Gain Following Q1 Earnings

US stocks down at midday, Dow down 0.2%, NASDAQ down 0.52%. Energy up 1.1%, consumer discretionary d

12 Health Care Stocks Moving In Monday's Intraday Session

US Stocks Mixed; Cleveland-Cliffs Shares Fall After Q1 Results

US stocks mixed, energy shares climb. Cleveland-Cliffs falls 6% after reporting Q1 results. Enveric

Reported Earlier: Passage Bio Receives FDA Guidance Requiring Randomized Registrational Trial For PB

Regulatory & Program UpdateThe Company has completed a Type C meeting with the FDA to seek guida

Reported Earlier: Passage Bio Initiates Strategic Review, Exploring Mergers, Acquisitions, Partnersh

Corporate UpdateThe Company has initiated a review of strategic alternatives to maximize shareholder

12 Health Care Stocks Moving In Monday's Pre-Market Session

Passage Bio Reports Updated Data From Ongoing Phase 1/2 upliFT-D Clinical Trial Evaluating PBFT02 Fo

PBFT02 administration resulted in improvements in two disease progression biomarkers, as compared to

Passage Bio Reports Updated Interim Data from upliFT-D Trial and Provides Regulatory and Corporate U

PBFT02 administration resulted in improvements in two disease progression biomarkers, as compared to

12 Health Care Stocks Moving In Friday's Pre-Market Session

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Oppenheimer Initiates Coverage On Passage Bio with Outperform Rating, Announces Price Target of $30

Oppenheimer analyst Jay Olson initiates coverage on Passage Bio (NASDAQ:PASG) with a Outperform r

12 Health Care Stocks Moving In Thursday's Pre-Market Session

Analysts Set Passage Bio, Inc. (NASDAQ:PASG) PT at $42.67

Shares of Passage Bio, Inc. (NASDAQ: PASG - Get Free Report) have received a consensus recommendatio

Canaccord Genuity Maintains Buy on Passage Bio, Lowers Price Target to $23

Canaccord Genuity analyst Whitney Ijem maintains Passage Bio (NASDAQ:PASG) with a Buy and lowers

Passage Bio Q4 EPS $(4.09) Misses $(2.68) Estimate

Passage Bio (NASDAQ:PASG) reported quarterly losses of $(4.09) per share which missed the analyst co

Passage Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Recent Business

Enrolled first three FTD-GRN patients in Cohort 3 of ongoing upliFT-D study Treated first FTD-C9orf7

Passage Bio to Participate in Upcoming Investor Conferences

PHILADELPHIA, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage g

Brokerages Set Passage Bio, Inc. (NASDAQ:PASG) Target Price at $42.67

Passage Bio, Inc. (NASDAQ: PASG - Get Free Report) has been assigned an average rating of "Moderate

Brokerages Set Passage Bio, Inc. (NASDAQ:PASG) Price Target at $42.67

Passage Bio, Inc. (NASDAQ: PASG - Get Free Report) has been given an average rating of "Moderate Buy

12 Health Care Stocks Moving In Monday's Intraday Session

Analyzing Passage Bio (NASDAQ:PASG) and Vir Biotechnology (NASDAQ:VIR)

Passage Bio (NASDAQ: PASG - Get Free Report) and Vir Biotechnology (NASDAQ: VIR - Get Free Report) a

Financial Comparison: Passage Bio (NASDAQ:PASG) versus PepGen (NASDAQ:PEPG)

Passage Bio (NASDAQ: PASG - Get Free Report) and PepGen (NASDAQ: PEPG - Get Free Report) are both sm

Brokerages Set Passage Bio, Inc. (NASDAQ:PASG) Target Price at $42.67

Passage Bio, Inc. (NASDAQ: PASG - Get Free Report) has been assigned an average rating of "Moderate

Chardan Capital Maintains Buy on Passage Bio, Raises Price Target to $21

Chardan Capital analyst Geulah Livshits maintains Passage Bio (NASDAQ:PASG) with a Buy and raises

Passage Bio Q3 EPS $(2.44) Beats $(2.80) Estimate

Passage Bio (NASDAQ:PASG) reported quarterly losses of $(2.44) per share which beat the analyst cons

Passage Bio Reports Third Quarter 2025 Financial Results and Provides Recent Business Highlights

Actively enrolling Cohort 3 (FTD-GRN) and Cohort 4 (FTD-C9orf72) patients in ongoing upliFT-D study

Passage Bio to Present at Guggenheim Securities 2nd Annual Healthcare Innovation Conference

PHILADELPHIA, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage g

Passage Bio to Participate in Chardan's 9th Annual Genetic Medicines Conference

PHILADELPHIA, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage g

zacks.com

Wall Street Analysts Think Passage Bio (PASG) Could Surge 731%: Read This Before Placing a Bet

The mean of analysts' price targets for Passage Bio (PASG) points to a 731% upside in the stock. Whi

Passage Bio to Participate in H.C. Wainwright 27th Annual Global Investment Conference

PHILADELPHIA, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage g

zacks.com

Wall Street Analysts Believe Passage Bio (PASG) Could Rally 1415.15%: Here's is How to Trade

The mean of analysts' price targets for Passage Bio (PASG) points to a 1415.2% upside in the stock.

Canaccord Genuity Maintains Buy on Passage Bio, Lowers Price Target to $67

Canaccord Genuity analyst Whitney Ijem maintains Passage Bio (NASDAQ:PASG) with a Buy and lowers

Guggenheim Maintains Buy on Passage Bio, Lowers Price Target to $10

Guggenheim analyst Debjit Chattopadhyay maintains Passage Bio (NASDAQ:PASG) with a Buy and lowers

Wedbush Maintains Outperform on Passage Bio, Raises Price Target to $40

Wedbush analyst Yun Zhong maintains Passage Bio (NASDAQ:PASG) with a Outperform and raises the pr

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

Passage Bio Q2 EPS $(2.96) Misses $(0.21) Estimate

Passage Bio (NASDAQ:PASG) reported quarterly losses of $(2.96) per share which missed the analyst co

Passage Bio Reports Second Quarter 2025 Financial Results and Provides Recent Business Highlights

Completed dosing of FTD-GRN Cohort 2 in upliFT-D study Reported updated interim data showing that PB

12 Health Care Stocks Moving In Friday's Intraday Session